Bio Pharma Dive
DECEMBER 7, 2021
Founded and led by Gary Glick, Odyssey Therapeutics has raised $218 million in an initial fundraising round for its cancer and inflammatory disease drug research.
World of DTC Marketing
DECEMBER 10, 2021
MY POINT : Success is always temporary. When all is said and one, the only thing you’ll have left is your character. Right now, I could make a great argument that Biogen’s character is trashed and that they are a company in dire need of authentic leadership. Massive layoffs could be headed to Biogen due to the disappointing rollout of its Alzheimer’s drug Aduhelm that generated only a few million dollars in revenue over the past two quarters.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Camargo
DECEMBER 10, 2021
Each month, Camargo’s “In the News” series highlights important changes and advancements in the regulatory and development space and explores how those changes could impact your program. Voxzogo Approved as a Growth-Improvement Therapy for Children with Dwarfism. Biomarin has obtained FDA accelerated approval for Voxzogo (vosoritide), its first-in-class drug to increase linear growth in pediatric achondroplasia patients over the age of 5 with open epiphyses (growth plates).
Outsourcing Pharma
DECEMBER 7, 2021
According to a leader from Cytoreason, AI isnât necessarily the best or only tool suited to discover new and novel therapiesâit might take a human touch.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Bio Pharma Dive
DECEMBER 8, 2021
Passage Bio and the University of Pennsylvania's Gene Therapy Program said they have begun preclinical research aimed at simultaneously developing multiple approaches to treating Huntington's.
World of DTC Marketing
DECEMBER 8, 2021
LEAD-IN- Recent data confirms that health care professionals are using the Internet more and spending less time with drug company reps. How much should you spend on an HCP portal, and how do you measure its success? One of the first questions I often get from potential clients is, “how much does a good HCP website cost?” There is no one answer to that question.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharma Times
DECEMBER 9, 2021
In a new report from The Institute of Cancer Research (ICR), data from cancer trials alongside assessments from clinicians and patients aims to provide guidance on how to improve services
Bio Pharma Dive
DECEMBER 9, 2021
The amount of blood clotting protein found in patients who received the medicine was nearly the same at six months and 18 months post-treatment, according to results disclosed Thursday.
World of DTC Marketing
DECEMBER 9, 2021
LEAD IN: Pharma budgets are being scrutinized like never before, and DTC/HCP marketers must justify every dollar spent. I’m getting more requests to measure and justify spending for specific bucket tactics, and I believe once politicians get focused, they will scrutinize drug pricing and force negotiations with Medicare tightening internal expenditures even more.
Pharma Mirror
DECEMBER 9, 2021
UAE, Abu Dhabi , Abu Dhabi has set its sights on Belgium, as a leading global pharmaceutical hub, to establish a global distribution corridor to serve the world in vaccine delivery and future life science needs. The collaboration builds on the capabilities of Abu Dhabi’s healthcare sector as a leading life sciences hub and the efforts of the HOPE Consortium in providing vaccine solutions for the world.
BioSpace
DECEMBER 9, 2021
?A U.S. Congress subcommittee unanimously approved the ACT for ALS bill in a decision that could soon pour massive funding into the search for treatment for this debilitating and deadly disease.
Bio Pharma Dive
DECEMBER 7, 2021
The vaccine, which Medicago plans to soon submit to Canadian regulators, would be the first of its type, though supply appears likely to be limited.
Pharma Times
DECEMBER 7, 2021
According to clinical data, Roche’s new COVID-19 treatment Actemra/RoActemra lowered mortality risk in critically ill adult patients.
Pharma Mirror
DECEMBER 9, 2021
Combatting the pandemic has highlighted the importance of the partnership between biopharma organizations and the contract manufacturing organizations (CMOs) that must flexibly handle outsourced production, which can come suddenly and often must quickly be ramped up. For example, to meet the urgent need for COVID-19 related therapies and vaccines early in the pandemic, Thermo Fisher Scientific, a world leader in serving science with annual revenue of approximately $35 billion, had to expand its
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
pharmaphorum
DECEMBER 9, 2021
AstraZeneca’s antibody cocktail for COVID-19, now called Evushield, has become the first drug in the class to be authorised for prevention of infection by the US FDA. The long-acting antibody combination, formerly known as AZD7442 (tixagevimab and cilgavimab) has been cleared for pre-exposure prophylaxis (PrEP) of COVID-19 in adults and adolescents aged 12 and older who weigh at least 40kg and have compromised immunity.
Bio Pharma Dive
DECEMBER 10, 2021
Updated Phase 2 data suggested an experimental drug targeting the protein TIGIT could bolster the benefit of Roche's Tecentriq in certain people with advanced lung cancer.
Pharma Times
DECEMBER 8, 2021
A senior official at the World Health Organisation (WHO) has said that Omicron is ‘highly unlikely’ to fully bypass vaccine protections.
XTalks
DECEMBER 8, 2021
B.T. Sweet, an Israeli food tech startup, recently unveiled a plant-based, one-to-one drop-in sugar substitute called Cambya. It can replace sugar in a multitude of applications in the chocolate and confectionary space, boasting the same levels of sweetness and body as real sugar. So, what is Cambya and what differentiates it from other sugar substitutes?
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
pharmaphorum
DECEMBER 6, 2021
UK artificial intelligence specialist BenevolentAI has said it will float on the Amsterdam Euronext exchange in what is being touted as Europe’s largest ever special purpose acquisition company (SPAC) deal. BenevolentAI will merge with Odyssey Acquisition, a SPAC set up by investment bankers Michael and Yoel Zaoui that lists former Sanofi chief executive Olivier Brandicourt among its advisors – in a deal that will raise some €390 million in proceeds.
Bio Pharma Dive
DECEMBER 10, 2021
The collaboration with Regor Therapeutics is another example of large pharma companies' interest in partnering with emerging biotechs from China.
Pharma Times
DECEMBER 10, 2021
In October 2021, over 356,000 people in England had been waiting for over six weeks for a key diagnostic test
BioPharma Reporter
DECEMBER 6, 2021
The European Medicines Agency (EMA) has started a rolling review of VLA2001, Valnevaâs COVID-19 vaccine candidate, with the company set to supply up to 60 million doses to the European Union.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
BioSpace
DECEMBER 8, 2021
Researchers published a study proving that SARS-CoV-2 infects human adipose or fat tissue to multiply and elicit an inflammatory response corresponding with severe COVID-19.
Bio Pharma Dive
DECEMBER 7, 2021
The alliance follows AstraZeneca's buyout of Alexion last year and puts the British drugmaker in competition with Alnylam, Bridgebio and several others.
Pharma Times
DECEMBER 7, 2021
Results show support in favour of heterologous dosing which may help to advance vaccination programmes in poorer countries.
XTalks
DECEMBER 10, 2021
Each year, food delivery platform Grubhub releases its “Year in Food” report, which analyzes millions of deliveries and highlights top orders. This year, the Impossible Cheeseburger made with plant-based ingredients beat out the spicy chicken sandwich for the top order position, increasing in popularity by 442 percent in 2021. Here are some more notable statistics from Grubhub’s “Year in Food” report.
BioSpace
DECEMBER 7, 2021
The company could lay off as many as 1,000 employees as it continues to deal with the controversial treatment.
Bio Pharma Dive
DECEMBER 8, 2021
The payment resolves the government's claims against Vyera and Phoenixus for their efforts to block competition to Daraprim, the toxoplasmosis drug Shkreli famously raised the price of by 4,000%.
Pharma Times
DECEMBER 10, 2021
The treatments are being offered as an addition to vaccinations to maximise protection against COVID-19
pharmaphorum
DECEMBER 9, 2021
Heather Barnes, external innovation lead EMEA at Johnson and Johnson Consumer Health, is a scientist who is truly passionate about consumer health. With her background in biochemistry and eye for identifying innovation trends, the future is bright at Johnson & Johnson Innovation. After making her way from early-stage drug development research to her current role, Heather got straight to work on creating sustainable collaborations that made life better for people and their families.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Expert insights. Personalized for you.
352 
Let's personalize your content